David Taylor
#108,212
Most Influential Person Now
British pharmaceutical scientist
David Taylor 's AcademicInfluence.com Rankings
David Taylor chemistry Degrees
Chemistry
#5363
World Rank
#6528
Historical Rank
Organic Chemistry
#947
World Rank
#1064
Historical Rank
Download Badge
Chemistry
David Taylor 's Degrees
- PhD Pharmaceutical Sciences University of Oxford
- Masters Pharmaceutical Sciences University of Oxford
Why Is David Taylor Influential?
(Suggest an Edit or Addition)According to Wikipedia, David Taylor FFRPS FRPharmS is a British professor. He is the head of the Pharmaceutical Sciences Clinical Academic Group within King's Health Partners. Taylor has been lead author and editor of the Maudsley Prescribing Guidelines in Psychiatry since 1994. In 2014, Taylor was named as one of the top 100 clinical leaders in the UK National Health Service.
David Taylor 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (1083)
- Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology (2009) (792)
- The Maudsley Prescribing Guidelines in Psychiatry (2015) (701)
- Delivering affordable cancer care in high-income countries. (2011) (656)
- Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines (2015) (508)
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017) (431)
- The Maudsley Prescribing Guidelines (2009) (388)
- The growing burden of cancer in India: epidemiology and social context. (2014) (328)
- Hypertensive Interactions Between Monoamine Oxidase Inhibitors and Foodstuffs (1967) (237)
- Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. (2006) (227)
- Chronic illness, expert patients and care transition. (2007) (212)
- Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (201)
- Psychiatrists’ attitude towards and knowledge of clozapine treatment (2010) (196)
- Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia (2007) (184)
- International trends in clozapine use: a study in 17 countries (2017) (164)
- Acceptance of the mental illness label by psychotic patients: effects on functioning. (1989) (161)
- Optimizing clozapine treatment (2011) (146)
- Substance use among the mentally ill: prevalence, reasons for use, and effects on illness. (1994) (139)
- Atypical antipsychotics and hyperglycaemia (2001) (135)
- A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review (2001) (130)
- Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs (2004) (113)
- Practitioner attitudes to clozapine initiation (2014) (107)
- Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety (2008) (102)
- Acute bipolar mania: a systematic review and meta‐analysis of co‐therapy vs. monotherapy (2007) (99)
- Augmentation of clozapine with a second antipsychotic – a meta‐analysis of randomized, placebo‐controlled studies (2009) (87)
- Options for pharmacological management of obesity in patients treated with atypical antipsychotics (2002) (87)
- Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis (2022) (80)
- Comprar The Maudsley Prescribing Guidelines, 10th Edition | Shitij Kapur | 9781841846996 | Informa Healthcare (2009) (79)
- Refractory schizophrenia and atypical antipsychotics (2000) (76)
- Refractory schizophrenia and atypical antipsychotics (2000) (76)
- Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme (2008) (70)
- The effectiveness of psychological treatments for treatment‐resistant depression: a systematic review (2005) (67)
- Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring (2009) (66)
- Behavioural management of antipsychotic‐induced weight gain: a review (2003) (60)
- Psychotropic interactions with warfarin (2000) (59)
- Health resource utilization associated with switching to risperidone long‐acting injection (2006) (56)
- Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients (2013) (56)
- What do community pharmacists do?: results from a work sampling study in London (2014) (55)
- A decision analysis of long-term lithium treatment and the risk of renal failure (2012) (54)
- Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome (2014) (53)
- Paliperidone palmitate long‐acting injection – prospective year‐long follow‐up of use in clinical practice (2014) (51)
- Antipsychotic drug use and pneumonia: Systematic review and meta-analysis (2018) (49)
- Antidepressant interactions with warfarin (1998) (41)
- The practical management of refractory schizophrenia – the Maudsley Treatment REview and Assessment Team service approach (2014) (39)
- Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort – a four-year mirror image study (2016) (37)
- Risperidone long‐acting injection: a 6‐year mirror‐image study of healthcare resource use (2009) (35)
- Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? (2007) (35)
- Antimicrobial Surveillance in Idiopathic Parkinsonism: Indication‐Specific Improvement in Hypokinesia Following Helicobacter pylori Eradication and Non‐Specific Effect of Antimicrobials for Other Indications in Worsening Rigidity (2013) (35)
- Co‐administration of citalopram and clozapine: effect on plasma clozapine levels (1998) (30)
- Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? (2017) (26)
- The effect of nefazodone on clozapine plasma concentrations. (1999) (25)
- Distinct Pharmacokinetic Profile and Safety of a Fixed‐Dose Tablet of Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine (2010) (24)
- An evaluation of the variation and underuse of clozapine in the United Kingdom (2020) (24)
- A UK consensus on the administration of aripiprazole for the treatment of mania (2009) (23)
- Comprar The Maudsley Prescribing Guidelines In Psychatry | David Taylor | 9780470979488 | Wiley (2012) (22)
- Development of Antimicrobial Stewardship Programmes in Low and Middle-Income Countries: A Mixed-Methods Study in Nigerian Hospitals (2020) (22)
- Long‐term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality (2018) (20)
- Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017) (19)
- Risperidone long‐acting injection in practice – more questions than answers? (2006) (19)
- Clozapine and gastro‐oesophageal reflux disease (GORD) – an investigation of temporal association (2012) (19)
- Impact of pharmacy care upon adherence to cardiovascular medicines: a feasibility pilot controlled trial (2016) (19)
- Pharmacy care and adherence to primary and secondary prevention cardiovascular medication: a systematic review of studies (2014) (18)
- Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke (2016) (18)
- What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication (2017) (17)
- Pharmacodynamics and pharmacokinetics (2020) (16)
- Is a treat-to-target strategy in osteoporosis applicable in clinical practice? Consensus among a panel of European experts (2020) (15)
- Metformin for schizophrenia (2012) (14)
- A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks (2013) (13)
- A prospective 6‐month analysis of the naturalistic use of aripiprazole – factors predicting favourable outcome (2007) (13)
- Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review (2022) (12)
- South Asians living in the UK and adherence to coronary heart disease medication: a mixed- method study (2018) (11)
- The pharmaco-economics of atypical antipsychotics. (1999) (11)
- Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up (2010) (10)
- Individualisation or standardisation: trends in National Health Service prescription durations in England 1998–2009 (2012) (9)
- Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential. (2019) (9)
- Value based pricing for NHS medicines: magic bullet, counterfeit treatment or the mixture as before? (2009) (8)
- P.2.099 A prevalence study of impaired glucose tolerance and diabetes mellitus in hospitalized patients with schizophrenia (2003) (7)
- Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals (2021) (7)
- Asylums revisited. (1977) (6)
- Cancer burden and health systems in India 1 The growing burden of cancer in India: epidemiology and social context (2014) (6)
- Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations (2021) (6)
- Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study. (2022) (6)
- The political economics of cancer drug discovery and pricing (2020) (5)
- Fentanyl pectin nasal spray (FPNS) with PecSys®: efficacy, tolerability, and onset of action in the treatment of breakthrough cancer pain (BTCP) (2009) (5)
- Psychosis and depression associated with alteration to amiodarone therapy (2010) (5)
- Evaluation of the effectiveness and acceptability of the long-acting oral antipsychotic penfluridol: Illustrative case series (2021) (5)
- Alternative routes to oral antidepressant therapy: case vignette and literature review (2010) (5)
- Can (and will) governments afford personalized medicine? (2010) (5)
- Links between the amount of antipsychotic medication prescribed per population at general practice level, local demographic factors and medication selection (2020) (4)
- Increasing access to erectile dysfunction treatment via pharmacies to improve healthcare provider visits and quality of life: Results from a prospective real‐world observational study in the United Kingdom (2020) (4)
- Antipsychotic use and unexpected death: a hospital‐based case–control study (2015) (4)
- Vitamin D deficiency in schizophrenia implications for COVID-19 infection (2020) (4)
- Withdrawal-associated relapse is a potential source of bias. (2021) (3)
- Mobile telephone delivered contingency management for encouraging adherence to supervised methadone consumption: feasibility study for an RCT of clinical and cost-effectiveness (TIES) (2021) (3)
- Alternative Routes of Administration of Clozapine (2022) (3)
- Prevalence and characteristics of breakthrough pain in patients with chronic noncancer pain (2005) (3)
- Fentanyl pectin nasal spray (FPNS) with PecSys®: onset of action, consistency, and acceptability in breakthrough cancer pain (BTCP) (2009) (3)
- Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study (2022) (3)
- Zuclopenthixol acetate (Clopixol Acuphase) for rapid sedation. (1999) (3)
- Fatalities associated with gabapentinoids in England (2004–2020) (2022) (3)
- The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes. (2019) (3)
- Institutionalized paternalism? Stakeholders' views on public access to genetic testing (2006) (3)
- Sociology for Pharmacists: An Introduction, 2nd Edition (2004) (2)
- Reply: To PMID 24841141. (2014) (2)
- Point-of-care haematological monitoring during treatment with clozapine (2022) (2)
- COMMUNITY TREATMENT ORDERS, ETHNICITY, CONDITIONS AND PSYCHOTROPIC MEDICATION: THE FIRST SIX MONTHS (N=126) (2010) (2)
- (804): Open-label study of fentanyl effervescent buccal tablets in patients with noncancer pain and breakthrough pain: Patient preference assessment (2006) (2)
- Possible pharmacogenetic factors in clozapine treatment failure: a case report (2021) (2)
- Can we check serum lithium levels less often without compromising patient safety? (2021) (1)
- Safer use of clozapine (2022) (1)
- Some observations on hallucination: clinical application of some developments of Melanie Klein's work. (1983) (1)
- Opioids in non-cancer pain: Utilization of Oral Transmucosal Fentanyl Citrate (OTFC®) in chronic noncancer pain: A retrospective survey of 100 patients (2004) (1)
- The Experience of Chemotherapy-Induced Neutropenia: Quality-of-Life Interviews With Adult Cancer Patients (2011) (1)
- (768): Multi-study analysis of patients’ preference for fentanyl buccal tablet (FBT) in the management of breakthrough pain (2007) (1)
- The cutlass study: A pragmatic, multicentre trial of the effectiveness and costs of atypical antipsychotic drugs in schizophrenia (2000) (1)
- The straw man of prescribing in psychiatry (2015) (1)
- Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial (2023) (1)
- Increasing Access to Erectile Dysfunction Treatment via Pharmacies to Improve Healthcare Provider Visits and Quality of Life: Results from a Prospective Real-World Observational Study in the United Kingdom (2020) (1)
- Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections? (2022) (1)
- Clozapine for treatment resistance in early psychosis: a survey of UK clinicians’ training, knowledge and confidence (2022) (1)
- Antipsychotic polypharmacy prescribing and risk of hospital readmission (2017) (1)
- Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital (2022) (1)
- PHP52 A RANDOMIZED, OPEN-LABEL PREFERENCE STUDY OF GENGRAF® COMPARED TO NEORAL® IN STABLE SOLID-ORGAN TRANSPLANT RECIPIENTS (2002) (0)
- C.01.03 Making the most of our existing pharmacotherapies (2011) (0)
- Reply (2014) (0)
- Reply (2011) (0)
- C.08.03 Importance of preventing relapse – benefits and place of long-acting injectables in treatment of schizophrenia (2014) (0)
- Reply (2014) (0)
- 3-year naturalistic follow-up Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a (2012) (0)
- Reasons for admission to a general medical hospital for patients taking clozapine (2022) (0)
- A naturalistic evaluation and audit database of agomelatine (NEVADA): Clinical outcome at eighteen months (2011) (0)
- Reply: To PMID 24004162. (2014) (0)
- Risperidone versus olanzapine in a naturalistic setting: Comparison of costs and outcomes in 11 UK centres (2001) (0)
- C.07.03 Optimising care in schizophrenia: the challenge of treating early non-responders and treatment resistant patients (2016) (0)
- C.13.03 Pharmacology of the D2 partial agonists – what they bring to the table (2019) (0)
- Pharmacists have a global opportunity to help abolish tobacco-related harm (2007) (0)
- Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials (2022) (0)
- A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease (2016) (0)
- On spinning plates (2015) (0)
- 201) Prescriber perceptions regarding the prevalence and symptomatology of chronic migraine headache (2014) (0)
- Comprar Managing Cancer Breakthrough Pain | Taylor, D. | 9781908517760 | Springer (2013) (0)
- Opioids in non-cancer pain: Breakthrough pain in patients with chronic noncancer pain: Impact on quality of life and the effects of oral transmucosal fentanyl citrate (2004) (0)
- Correction to: The association between sarcopenia and quality of life in patients undergoing colorectal cancer surgery: an exploratory study (2021) (0)
- Golden opportunity for intervention? Identifying vitamin D deficiency in patients with substance use disorders in hospital (2022) (0)
- (206) Tolerability of once-daily cyclobenzaprine hydrochloride modified-release 15 mg and 30 mg for low back and neck pain associated with muscle spasm (2008) (0)
- A case–control study of antipsychotic use and pneumonia‐related mortality in the United Kingdom (2023) (0)
- Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses (2022) (0)
- Genetic Analysis of Clozapine Metabolism in a Patient With Subtherapeutic Clozapine Plasma Concentrations-The Importance of CYP3A5: A Case Report. (2022) (0)
- Dopamine partial agonists: a discrete class of antipsychotics. (2022) (0)
- Tardive dyskinesia: understanding current challenges in diagnosis and treatment (2023) (0)
- P.0831 Weekly oral treatments in psychiatry and the potential for once weekly dosing with aripiprazole (2021) (0)
- Socioeconomic Factors, Urological Epidemiology and Practice Patterns Re: Delivering Affordable Cancer Care in High-Income Countries (2011) (0)
- P.3.a.010 Risperidone long-acting injection: a one year observational study in a naturalistic setting (2006) (0)
- P.3.c.019 Community treatment orders and psychotropic medication: baseline data analysis for a one year follow up study (N= 200) (2010) (0)
- P.3.015 Community treatment orders, ethnicity, conditions and psychotropic medication: the first six months (N = 126) (2010) (0)
- P.0829 Aripiprazole – relationship of serum concentrations to clinical effects and implications for oral delivery (2021) (0)
This paper list is powered by the following services:
Other Resources About David Taylor
What Schools Are Affiliated With David Taylor ?
David Taylor is affiliated with the following schools:
